Summary 5-fluorouracil (5F-) is activated intracellularly to cytotoxic 5-fluoronucleotides (FNuct). These were detected non-invasivelv 
The xenobiotic 5-fluorouracil (5FU) is used mainly in the treatment of solid tumours such as colon, breast and head and neck tumours (Grem, 1990) . Although 5FU is the single most active drug against colon cancer (Mackintosh et al. 1987) it is normally used in combination with other drugs, particularly methotrexate (MTX) . Preclinical studies established that synergistic effects were obtained when MTX preceded SFU (MTX-5FU schedules) although the optimal scheduling of MTX-5FU combination chemotherapy appears to vary from one experimental tumour type to another (reviewed by Damon et al.. 1989) . A recent report (Marsh et al., 1991) demonstrated increased activity against advanced colon cancer when MTX preceded SFU by 24 h rather than 1 h, but not for rectal cancer and thus a universal optimum schedule has yet to be established in the clinic.
5FU cytotoxicity requires the anabolism of 5FU in the tumour to 5-fluoronucleotides (FNuct), see Figure 1 . FNuct include (a) 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) which stops DNA synthesis by inhibition of thymidylate synthase (TMPsyn), (b) 5-fluorouridine triphosphate (FUTP) which becomes incorporated into RNA, interfering with RNA maturation and (c) 5-fluoro-2'-deoxyuridine triphosphate (FdUTP) which can be misincorporated into DNA (Pinedo & Peters, 1988) . However, FdUTP is probably removed from DNA by uracil-DNA glycosylase and thus may not be important in 5FU cytotoxicity (reviewed by Pinedo & Peters, 1988) . These and other fluoronucleotides may be detected non-invasively by the technique of '9F-nuclear magnetic resonance spectroscopy . In vitro the different nucleotides can be resolved (Vialaneix et al., 1986) , but in vivo they appear as a single peak which also includes signals from FUMP, FUDP and the FUDP-sugars; this FNuct peak remains clearly resolved from the parent drug, the fluoro-catabolites or the 5-fluoronucleosides (FNucs) . lung tumour in mice (Stevens et al.. 1984) and has subsequently been detected in numerous mouse and rat tumours (reviewed by McSheehy & Griffiths. 1989 ) and more recently in the liver metastases of patients (Semmier et al.. 1990 ). In rats bearing the Walker carcinosarcoma (WK tumour) we demonstrated that the intensity of this FNuct peak in vivo could predict SFU toxicity towards that tumour. suggesting a clinical role for '9F-MRS . MTX is a chemotherapeutic agent that does not require metabolic activation to exert cytotoxic effects although they are sustained by intracellular polyglutamation of MTX. MTX causes inhibition of de novo purine synthesis through depletion of intracellular reduced folates which causes a rise in the cytoplasmic 5-phosphoribosyl-1-pyrophosphate (PRPP) concentration (Damon et al.. 1989) . In tumour cells where SFU is activated via orotate phosphoribosyl transferase. increased PRPP results in greater conversion of 5FU to FUMP and thus FNuct (Figure 1) . Wayss et al. (1985) Acid extracts and hplc Tumour extracts were made (2.5 g from each tissue) using 10 ml of cold 6% (v v) perchlonrc acid and were neutralised with KOH. The extracts were freeze-dried and concentrated to a 2.5 ml solution. Aliquots (200 p1) were stored at -20'C for hplc and the remainder analysed by MRS. Spectra (6-7000 transients with a spectral width of 6 or 8 kHz) were obtained in vitro using a solenoid coil with 9 p.sec pulses (flip angle = 90°) and a TR of 8.5 s from a 2 ml solution containing 200 (Figure 2b ). FNucs or catabolites of 5FU such as m-fluoro-p-alanine (FBal) and a-fluoroureidopoprionic acid (FUPA) were not visible in vivo at these doses. FNuct increased with time at a rate which appeared to exhibit zeroorder kinetics, while the 5FU signal decreased exponentially until 50 min when the areas of the peaks were similar. Pretreatment of the animal with MTX using either a regimen of 50 mg kg-' 3 h prior to 5FU (regimen 1) or 20 mg kg-' 24 h prior to 5FU (regimen 2) caused a faster rate of FNuct formation resulting in an increased peak area after 50mmn (Figure 2a) . These two patterns of metabolism were reproducible and the results from twelve animals are summarised in Figure 3 . Where animals were pretreated with either regimen of MTX, formation of FNuct reached a maximum before the end of the experiment (at around 40 min), whereas the 5FU signal declined during 50 min in a manner similar to that of the controls. 5FU disappearance exhibited first-order kinetics, enabling the calculation of a t1 of around 17 min which clearly was unaltered by regimens 1 or 2. In contrast the rate of FNuct formation was significantly increased about 3-fold (P < 0.002) ( Table I) . Using an MTX dose of 20 mg kg-' i.p. three other time intervals of 3, 6 or 12 h prior to 5FU administration were investigated. These produced very similar patterns of metabolism to those shown in Figure   3 (data not shown).
When 5FU was injected at the same 50 mg kg-' dose but i.p. instead of i.v., '9F signals were not visible at the field strength of 1.9 T although we have subsequently found that 5FU, FNuct and FPia can be observed at 4.7 T from a similar dose (results not shown). At a dose of 120 mg kg-' i.p. 5FU was always visible and in 3 of 4 tumours FNuct was seen 30 min after injection and then increased at a rate similar to that following the 50 mg kg-' i.v. dose ( Figure 4a , Table I ). Pre creased by about 3-fold the rate of FNuct formation (P < 0.002) and the final amount of FNuct (P < 0.05) ( Figure   4B , Table I ).
Tumour extracts from animals treated by 5FU i.v. were analysed quantitatively bv MRS in vitro. This analysis confirmed that FNuct was increased 2-3 fold when rats were pre-treated with MTX. while less of the parent drug was visible compared to extracts from controls ( Figure 5) Figure 6a which shows the effect of combining MTX and 5FU using the dose regimen 1 (see Methods). This combination completely arrested growth. although the MTX-5FU schedule was no more effective than the reverse schedule of 5FU-MIX. Both these schedules with higher doses of MTX were fairly toxic causing up to 10% body weight loss relative to controls, the MTX-5FU schedule being the more toxic (Table  III) . When the MTX dose was reduced to 20 mg kg' and the interval between treatments was extended (regimen 2) there was a significant difference in cytotoxicity between the MTX-5FU and 5FU-MTX treatment schedules (Figure 6b ). The MTX-5FU schedule was the most cytotoxic and was indeed the only schedule to cause a cessation of growth. There was again significant body weight loss relative to controls which was once more least in the 5FU-MTX schedule and similarly high in the MTX alone and MTX-5FU schedules (Table III) Samples are the same as those shown in Figure 3 . Results in vivo show the final time-point (50 min) in arbitrary units while in vitro the final time-point was 67 min. All values are the mean ± s.e. of four tumours for each different treatment schedule, where treatment with 5FU was always 50kg kg-' i.v. and pre-treatment with MTX (i.p.) was either 50 mg kg-' 3 h pnror to 5FU or 20 mg kg-24 h prior to 5FU. Quantitation of the extracts was by MRS in vitro and hplc. 'P <0.02. (Schwartz 1979 : Cadman et & Griffiths, 1991 Damon et al., 1989 ). This effect is prob increase in intracellular levels of PRPI been demonstrated in many cell lines : Benz et al.. 1982 ) (Houghton et al.. 1982) .
In this report we have shown in vivo ti MTX from 3 to 24 h prior to the injectio a very rapid formation of FNuct so th, administration there was a 3-fold incre a administration. and this doubled the t4 for 5FU disappearance possibly due to a continuous supply of 5FU from the blood as anabolism in the tumour proceeded (Table I) . 9 10 11
Catabolism of 5FU is probably not significant in this tumour (see below). However, it seemed clear that once 5FU entered the tumour FNuct was formed at a rate that was indepen--th bv different MTX dent of the dose or mode of administration. Furthermore. the *ere initiated and the effect of MTX was always to increase the rate of formation Treatments (all i.p.)
of FNuct about 3-fold (Table I) . It is interesting to note the NaCl 0 [Control( 1)].
t, value for 5FU disappearance in the tumour was con-)mgkg-') V [MTXsistently found to be around 17 mn when 50 mg kg-' 5FU NX. b. (24 h interval):
was administered i.v. (Table I ). In the liver of these rats s')followed by 5FU following a similar dose of 5FU (60mg kg-' i.v.) the t-was e sechedule A . Results show the found to be 5 min (Prior et al.. 1990) . suggesting that 5FU is )up 'P<0.0001 comlikely to persist in non-hepatic tissues. red to control(2) and
The effect of MTX to increase the rate of FNuct formation Ing Gabnel's one-way appeared to be independent of the time intervals (3. 6. 12 or 24 h) that we used. Other investigators using cell lines in *itro . Benz et al.. 1982 or tumours grown in vivo (Brown & Ward, 1978 : Herrmann et al.. 1985 have found the length of time by which MTX precedes 5FU to be to increased cvtotoximportant for obtaining maximum 5FU activation. Figure 6b ). This high sensitivity of the WK tumour to MTX explained the absence of a difference between the 5FU-MTX and MTX-5FU schedules in the preliminary experiment where a higher MTX dose (50 mg kg-') was used in combination with a single dose of 5FU alone that was known not to affect growth at all (Figure 6a ). However, in regimen 2 when the MTX dose was 20 mg kg-' the MTX-5FU schedule was the only one that caused significant inhibition of tumour growth (Figure 6b ). In any event, a higher FNuct formation in viivo predicted increased cytotoxicity when MTX preceded 5FU as opposed to a dose of 5FU alone. We were unable to detect '9F-signals 3 or 24 h after injection of 50mgkg-1 5FU i.v. whether MTX was administered or not.
Combination chemotherapy where MTX precedes 5FU causes toxicity in gastrointestinal tissue rather than bonemarow (see for example Houghton et al.. 1982 and reviewed by Damon et al.. 1989) . Thus a change in body weight is a valid parameter by which to assess toxicity. Relative to controls the toxicity of the MTX-5FU regimes. although significant. was not excessive (Table III) . However, when 5FU preceded MTX (reverse schedule) there was both less cytotoxicity ( Figure 6b ) and less general toxicity compared to the MTX alone or MTX-5FU schedule (Table III) . This type of effect is not surprising since 5FU can antagonise the anti-purine effect of MTX (Grem. 1990 
